Elsevier

Brain Research

Volume 718, Issues 1–2, 29 April 1996, Pages 217-220
Brain Research

Damage to dopaminergic nerve terminals in mice by combined treatment of intrastriatal malonate with systemic methamphetamine or MPTP

https://doi.org/10.1016/0006-8993(96)00135-7Get rights and content

Abstract

The mechanisms involved in methamphetamine (METH)-induced damage to nigrostriatal dopaminergic neurons in experimental animals are unknown. We have examined the possibility that perturbations in energy metabolism contribute to METH-induced toxicity by investigating the effects of systemic METH treatment in mice which received a unilateral intrastriatal infusion of malonate, a metabolic inhibitor which decreases ATP levels. Malonate (1–4 μmol) produced a dose-dependent decrease in striatal dopamine (DA). The combined treatment of intrastriatal malonate with systemic METH resulted in greater damage to dopaminergic neurons than by METH or malonate treatment alone. In parallel studies, MPTP was administered to mice which received intrastriatal infusions of saline or malonate. Similar to results obtained with METH, decreases in striatal DA content and tyrosine hydroxlase (TH) activity were greatest in MPTP-treated mice infused with malonate. The present results lend credence to the hypothesis that METH-induced increases in energy utilization create a state of metabolic stress for DA neurons which may ultimately contribute to the neurodegenerative effects of METH. Moreover, the fording that combined malonate and MPTP treatment produced greater damage than either substance alone is consistent with the hypothesis that perturbations in energy metabolism contribute to the neuronal death produced by MPP+.

References (18)

There are more references available in the full text version of this article.

Cited by (34)

  • The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism

    2013, Experimental Neurology
    Citation Excerpt :

    Mice were euthanized 15 h, 3 days or 7 days after treatment. We and others have shown that the mouse MPTP model produces extensive loss of striatal nerve terminals and of nigral DA neurons (Albers et al., 1996; German et al., 1996; Giovanni et al., 1994; Liang et al., 1996). The dose of captopril was selected based on previous studies (Munoz et al., 2006).

View all citing articles on Scopus
View full text